Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (Nasdaq: AZN) reported on Wednesday that its Phase III RESOLUTE trial of Fasenra (benralizumab) in chronic obstructive pulmonary disease (COPD) did not achieve statistical significance on the primary endpoint, despite showing numerical improvements.

The safety and tolerability profile was consistent with previous findings. AstraZeneca will analyse the full data set before sharing results with the scientific community.

Fasenra is already approved in more than 80 countries, including the US, Japan, EU and China, as an add-on maintenance therapy for severe eosinophilic asthma. It is also approved in over 60 countries for eosinophilic granulomatosis with polyangiitis and is under regulatory review for hypereosinophilic syndrome.

AstraZeneca continues to expand its Respiratory & Immunology portfolio, which has been a key growth driver for the company alongside its wider focus in oncology, rare diseases and biopharmaceuticals.